Despite advances in the treatment paradigm of patients with acute myeloid leukemia (AML), TP53-mutated AML represents a molecular subgroup that has failed to improve, with an overall survival of ∼6 months that is independent of age and fitness. Notably, there has been significant elucidation in understanding the biology of the disease and key advancements in the classification and prognostication of these patients. International collaborative efforts of novel clinical interventions are urgently needed to change the standard of care.

中文翻译：

---

TP53 突变的急性髓系白血病：我们如何改善预后？


尽管急性髓系白血病 (AML) 患者的治疗模式取得了进展，但 TP53 突变的 AML 代表了一个未能改善的分子亚组，其总生存期约为 6 个月，与年龄和健康状况无关。值得注意的是，在了解该疾病的生物学以及这些患者的分类和预后方面的关键进展方面已经有了重要的阐明。迫切需要新的临床干预措施的国际合作努力来改变护理标准。